Abstract Number: 2708 • 2018 ACR/ARHP Annual Meeting
Current Management of Early Diffuse Cutaneous Systemic Sclerosis in US Scleroderma Centers
Background/Purpose: Standard treatment for the diverse aspects of diffuse cutaneous systemic sclerosis (dcSSc) is not yet well defined although experts have described therapeutic algorithms. The…Abstract Number: 2709 • 2018 ACR/ARHP Annual Meeting
Conversion of Normal Mean Pulmonary Arterial Pressure to Pulmonary Hypertension in Systemic Sclerosis – a Longitudinal Observational Study
Background/Purpose: Pulmonary hypertension (PH) is one of the leading causes of mortality in patients with systemic sclerosis (SSc). Active screening detects PH earlier and may…Abstract Number: 2710 • 2018 ACR/ARHP Annual Meeting
Physical Activity Trackers Work Well As a Monitor of Physical Activity in Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) patients have reduced physical function, exercise capacity and health related quality of life (HRQOL). The objective of this study was to…Abstract Number: 2711 • 2018 ACR/ARHP Annual Meeting
Comparison of Gastric Antral Vascular Ectasia Associated with Systemic Sclerosis with That Associated with Other Diseases: Are There Differences?
Background/Purpose: Gastric antral vascular ectasia (GAVE) is a pathologic angioectasia with a characteristic endoscopic appearance. Rugal folds with dilated blood vessels radiate from the antrum…Abstract Number: 2712 • 2018 ACR/ARHP Annual Meeting
Evaluation of Longitudinal Outcomes in Scleroderma Patients with Negative Immunofluorescent Anti-Nuclear Antibodies
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune disease characterized by inflammation, fibrosis, and vasculopathy. Historical data indicates approximately 90% of patients with SSc test positive…Abstract Number: 2713 • 2018 ACR/ARHP Annual Meeting
Is Effectiveness of Immunosuppression for Interstitial Lung Disease in Systemic Sclerosis (SSc) Modified By Lung Disease Severity or SSc Duration?
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of mortality in SSc. Immunosuppression is used to treat ILD, but little is known about its…Abstract Number: 2714 • 2018 ACR/ARHP Annual Meeting
Significance of Anti-Neutrophil Cytoplasmic Antibodies in Systemic Sclerosis
Background/Purpose: ANCA are detected in 0-11.7% (1) of patients with systemic sclerosis (SSc) and only a minority of these patients will develop an overlap syndrome with…Abstract Number: 2715 • 2018 ACR/ARHP Annual Meeting
The Effect of an Intensive Controlled 6-Moth Physical-Occupational Therapy Program with Subsequent 6-Month Follow-up Period in Patients with Systemic Sclerosis – Preliminary Data
Background/Purpose: Involvement of the skin and musculoskeletal system is associated with impaired quality of life in patients with systemic sclerosis (SSc). Data on efficacy of…Abstract Number: 2716 • 2018 ACR/ARHP Annual Meeting
A New Score to Predict Digital Ulcers Combining Clinical Data, Imaging and Patient History in Systemic Sclerosis
Background/Purpose: Ischemic complications such as digital ulcers (DU) are a common complication in systemic sclerosis (SSc) patients. The aim of this study was to combine…Abstract Number: 2717 • 2018 ACR/ARHP Annual Meeting
Factors Predicting Severe Infections in Patients with Systemic Necrotizing Vasculitides Based on Data from 733 Patients Enrolled in Randomized–Controlled Trials
Background/Purpose: Although overall survival of patients with systemic necrotizing vasculitides (SNVs) has improved markedly over the last 20 years, infectious complications remain a major cause…Abstract Number: 2718 • 2018 ACR/ARHP Annual Meeting
Comparison of Various ANCA Detection Methods in Predominantly MPO ANCA-Associated Vasculitis Cohort
Background/Purpose: In 2017, the multicenter European Vasculitis Study Group (EUVAS) evaluated the diagnostic accuracy of a wide spectrum of detection tests of MPO and PR3-ANCAs…Abstract Number: 2719 • 2018 ACR/ARHP Annual Meeting
Tracking the Risk of Infections in ANCA-Associated Vasculitis: Results from a Scottish Matched-Cohort Study
Background/Purpose: Evaluation of infection risk in ANCA-associated vasculitis (AAV) has been limited to small, selected populations and/or serious episodes. In this large study, we aimed…Abstract Number: 2720 • 2018 ACR/ARHP Annual Meeting
30-Day Hospital Readmission for Granulomatosis with Polyangiitis: Analysis from National Readmission Database
Background/Purpose: Granulomatosis with polyangiitis (GPA) is a systemic vasculitis with multi-organ involvement which can lead to frequent hospitalizations. Our study is to investigate characteristics and…Abstract Number: 2721 • 2018 ACR/ARHP Annual Meeting
Venous Thromboembolism in ANCA Associated Vasculitis. a Population-Based Cohort Study from Southern Sweden
Background/Purpose: To estimate the rate and predictors of venous thromboembolic events (VTEs) in a population-based cohort of patients with ANCA- associated vasculitis (AAV). Methods: 322…Abstract Number: 2722 • 2018 ACR/ARHP Annual Meeting
Incidence and Predictors of Severe Infections in ANCA Associated Vasculitis in a Population-Based Cohort – Preliminary Results
Background/Purpose: To determine the incidence rates, predictors and outcome of severe infections in ANCA associated vasculitis (AAV). Methods: We conducted a population-based cohort study in…